Navigation Links
MIT chemists engineer plants to produce new drugs
Date:11/3/2010

CAMBRIDGE, Mass. -- Humans have long taken advantage of the huge variety of medicinal compounds produced by plants. Now MIT chemists have found a new way to expand plants' pharmaceutical repertoire by genetically engineering them to produce unnatural variants of their usual products.

The researchers, led by Associate Professor Sarah O'Connor, have added bacterial genes to the periwinkle plant, enabling it to attach halogens such as chlorine or bromine to a class of compounds called alkaloids that the plant normally produces. Many alkaloids have pharmaceutical properties, and halogens, which are often added to antibiotics and other drugs, can make medicines more effective or last longer in the body.

The team's primary target, an alkaloid called vinblastine, is commonly used to treat cancers such as Hodgkin's lymphoma. O'Connor sees vinblastine and other drugs made by plants as scaffolds that she can modify in a variety of ways to enhance their effectiveness.

"We're trying to use plant biosynthetic mechanisms to easily make a whole range of different iterations of natural products," she said. "If you tweak the structure of natural products, very often you get different or improved biological and pharmacological activity."

O'Connor, graduate student Weerawat Runguphan and former postdoctoral associate Xudong Qu describe their engineered periwinkle plants in the Nov. 3 online edition of Nature. The research was funded by the National Institutes of Health and the American Cancer Society.

Engineering new genes into plants has been done before: In the 1990s, scientists developed corn that could produce an insecticide called Bt, which comes from a bacterial gene. However, O'Connor's approach, known as metabolic engineering, goes beyond simply adding a gene that codes for a novel protein. Metabolic engineers tinker with the series of reactions that the host organisms use to build new molecules, adding genes for new enzymes that reshape these natural synthetic pathways. This can lead to a huge variety of end products.

Most metabolic engineers use bacteria as their host organism, in part because their genes are easier to manipulate. O'Connor's work with plants makes her a rare exception. She doesn't believe one approach is better than the other, but one factor that drew her to engineer plants is that most plant synthetic pathways have not been completely revealed. "You can't reconstitute a whole plant pathway in bacteria unless you have all the genes," she said.

In previous experiments, O'Connor and her students induced periwinkle root cells to create novel compounds by feeding them slightly altered versions of their usual starting materials. In the new study, they engineered the cells to express genes that code for enzymes that attach chlorine or bromine to vinblastine precursors and other alkaloids.

The two new genes came from bacteria that naturally produce halogenated compounds. It's much more rare for plants to generate such compounds on their own, said O'Connor. It is also possible, though very difficult, to synthesize halogenated alkaloids in a laboratory.

To make alkaloids, plants first convert an amino acid called tryptophan into tryptamine. After that initial step, about a dozen more reactions are required, and the plants can produce hundreds of different final products. In the new genetically engineered plants, a bacterial enzyme called halogenase attaches a chlorine (or bromine) atom to tryptamine. That halogen stays on the molecule throughout the synthesis.

In future work, the researchers hope to engineer full periwinkle plants to produce the novel compounds. They are also working on improving the overall yield of the synthesis, which is about 15 fold lower than the plant's yield of naturally occurring alkaloids. One way to do that is to introduce the halogen further along in the process, said O'Connor.


'/>"/>

Contact: Jennifer Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. VA names UCI orthopedic biomedical engineer a senior research career scientist
2. Ming Hsieh donates $50 million to establish a USC institute for research on engineering medicine for cancer
3. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
4. Confectionery and chocolate engineering: Principles and applications
5. Engineering shorter wait times in the ER
6. Natural lung material is promising scaffold for engineering lung tissue using embryonic stem cells
7. Ellsworth Adhesives Announces New International Engineered Sales Representative
8. Surgeon-engineer team produce training software for robot-assisted surgery
9. Tissue engineers create a new way to assemble artificial tissues
10. UCLA engineer invents worlds smallest, lightest telemedicine microscope
11. University of Miami College of Engineering to develop new methods for data analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: